Abstract
Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high-dose dexamethasone-based therapies. Remission was observed in 22 patients (47%), including six patients with complete remission. Side-effects were frequent, mild and usually reversible, but deep vein thrombosis occurred in 8% of patients. Survival and remission times were longer among patients treated for previous resistant disease rather than for resistant relapse. This experience supports the use of thalidomide-dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 768-777 |
| Number of pages | 10 |
| Journal | British Journal of Haematology |
| Volume | 121 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jun 2003 |
Keywords
- Dexamethasone
- Multiple myeloma
- Thalidomide
ASJC Scopus subject areas
- Hematology